133 related articles for article (PubMed ID: 19936659)
1. Bone mineral density in children with steroid-sensitive nephrotic syndrome.
Mishra OP; Meena SK; Singh SK; Prasad R; Mishra RN
Indian J Pediatr; 2009 Dec; 76(12):1237-9. PubMed ID: 19936659
[TBL] [Abstract][Full Text] [Related]
2. Are children with idiopathic nephrotic syndrome at risk for metabolic bone disease?
Gulati S; Godbole M; Singh U; Gulati K; Srivastava A
Am J Kidney Dis; 2003 Jun; 41(6):1163-9. PubMed ID: 12776267
[TBL] [Abstract][Full Text] [Related]
3. Effect of two prophylactic bolus vitamin D dosing regimens (1000 IU/day vs. 400 IU/day) on bone mineral content in new-onset and infrequently-relapsing nephrotic syndrome: a randomised clinical trial.
Muske S; Krishnamurthy S; Kamalanathan SK; Rajappa M; Harichandrakumar KT; Sivamurukan P
Paediatr Int Child Health; 2018 Feb; 38(1):23-33. PubMed ID: 28466679
[TBL] [Abstract][Full Text] [Related]
4. Calcium and vitamin D for osteoprotection in children with new-onset nephrotic syndrome treated with steroids: a prospective, randomized, controlled, interventional study.
Choudhary S; Agarwal I; Seshadri MS
Pediatr Nephrol; 2014 Jun; 29(6):1025-32. PubMed ID: 24414607
[TBL] [Abstract][Full Text] [Related]
5. Three-monthly bolus vitamin D supplements (1000 vs 400 IU/day) for prevention of bone loss in children with difficult-to-treat nephrotic syndrome: a randomised clinical trial.
Singh DN; Krishnamurthy S; Kamalanathan SK; Harichandrakumar KT; Sivamurukan P
Paediatr Int Child Health; 2018 Nov; 38(4):251-260. PubMed ID: 30092157
[TBL] [Abstract][Full Text] [Related]
6. Acute alteration in bone mineral density and biochemical markers for bone metabolism in nephrotic patients receiving high-dose glucocorticoid and one-cycle etidronate therapy.
Fujita T; Satomura A; Hidaka M; Ohsawa I; Endo M; Ohi H
Calcif Tissue Int; 2000 Mar; 66(3):195-9. PubMed ID: 10666494
[TBL] [Abstract][Full Text] [Related]
7. Dual energy X-ray absorptiometry outcomes in male COPD patients after treatment with different glucocorticoid regimens.
Dubois EF; Röder E; Dekhuijzen PN; Zwinderman AE; Schweitzer DH
Chest; 2002 May; 121(5):1456-63. PubMed ID: 12006428
[TBL] [Abstract][Full Text] [Related]
8. Bone mineral density and its influencing factors in children with idiopathic nephrotic syndrome: a prospective observational study.
Sharawat IK; Dawman L; Kumkhaniya MV; Devpura K; Mehta A
Trop Doct; 2019 Oct; 49(4):292-298. PubMed ID: 31408410
[TBL] [Abstract][Full Text] [Related]
9. Long-term, high-dose glucocorticoids and bone mineral content in childhood glucocorticoid-sensitive nephrotic syndrome.
Leonard MB; Feldman HI; Shults J; Zemel BS; Foster BJ; Stallings VA
N Engl J Med; 2004 Aug; 351(9):868-75. PubMed ID: 15329424
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of body weight vs body surface area-based prednisolone regimen in nephrotic syndrome.
Basu B; Bhattacharyya S; Barua S; Naskar A; Roy B
Clin Exp Nephrol; 2020 Jul; 24(7):622-629. PubMed ID: 32201918
[TBL] [Abstract][Full Text] [Related]
11. Effect of glucocorticoids on growth and bone mineral density in children with nephrotic syndrome.
Ribeiro D; Zawadynski S; Pittet LF; Chevalley T; Girardin E; Parvex P
Eur J Pediatr; 2015 Jul; 174(7):911-7. PubMed ID: 25573461
[TBL] [Abstract][Full Text] [Related]
12. Longitudinal follow-up of bone mineral density in children with nephrotic syndrome and the role of calcium and vitamin D supplements.
Gulati S; Sharma RK; Gulati K; Singh U; Srivastava A
Nephrol Dial Transplant; 2005 Aug; 20(8):1598-603. PubMed ID: 15956073
[TBL] [Abstract][Full Text] [Related]
13. Bone mineral density in children with relapsing nephrotic syndrome: A hospital-based study.
Jesmin T; Al Mamun A; Rahman MA; Santa SM; Huque SS; Begum A; Roy RR; Rahman MH; Uddin GM
Saudi J Kidney Dis Transpl; 2019; 30(6):1415-1422. PubMed ID: 31929289
[TBL] [Abstract][Full Text] [Related]
14. Prophylactic calcium and vitamin D treatments in steroid-treated children with nephrotic syndrome.
Bak M; Serdaroglu E; Guclu R
Pediatr Nephrol; 2006 Mar; 21(3):350-4. PubMed ID: 16382319
[TBL] [Abstract][Full Text] [Related]
15. Short-Duration Prednisolone in Children with Nephrotic Syndrome Relapse: A Noninferiority Randomized Controlled Trial.
Kainth D; Hari P; Sinha A; Pandey S; Bagga A
Clin J Am Soc Nephrol; 2021 Feb; 16(2):225-232. PubMed ID: 33478976
[TBL] [Abstract][Full Text] [Related]
16. Bone mineral content and collagen metabolites in children receiving steroid treatment for nephrotic syndrome.
Esbjörner E; Arvidsson B; Jones IL; Palmér M
Acta Paediatr; 2001 Oct; 90(10):1127-30. PubMed ID: 11697422
[TBL] [Abstract][Full Text] [Related]
17. Use of a low-dose prednisolone regimen to treat a relapse of steroid-sensitive nephrotic syndrome in children.
Raja K; Parikh A; Webb H; Hothi D
Pediatr Nephrol; 2017 Jan; 32(1):99-105. PubMed ID: 27677978
[TBL] [Abstract][Full Text] [Related]
18. Long term tapering versus standard prednisolone treatment for first episode of childhood nephrotic syndrome: phase III randomised controlled trial and economic evaluation.
Webb NJA; Woolley RL; Lambe T; Frew E; Brettell EA; Barsoum EN; Trompeter RS; Cummins C; Deeks JJ; Wheatley K; Ives NJ;
BMJ; 2019 May; 365():l1800. PubMed ID: 31335316
[TBL] [Abstract][Full Text] [Related]
19. The deleterious effects of low-dose corticosteroids on bone density in patients with polymyalgia rheumatica.
Pearce G; Ryan PF; Delmas PD; Tabensky DA; Seeman E
Br J Rheumatol; 1998 Mar; 37(3):292-9. PubMed ID: 9566670
[TBL] [Abstract][Full Text] [Related]
20. The effect of vitamin D and calcium supplementation in pediatric steroid-sensitive nephrotic syndrome.
Banerjee S; Basu S; Sen A; Sengupta J
Pediatr Nephrol; 2017 Nov; 32(11):2063-2070. PubMed ID: 28725977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
